Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLS4/RTV and TAF DDI Study in Healthy Subjects
NCT04551261Phase 1Completed
- Sponsor
- Sunshine Lake Pharma
- Start
- Jan 2021
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of moroxydine in Chronic Hepatitis B (CHB) (2 arms), sponsored by Sunshine Lake Pharma. Primary endpoints: Maximum Plasma Concentration, Area Under the Curve and 1 more. Started Jan 2021; status: completed.
02
Drugs
moroxydine
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT04551261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04551261.